Cue Biopharma, Inc. Stock-Based Compensation
Cue Biopharma, Inc. (CUE) reported Stock-Based Compensation of $23.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $23.84M, a 1787.41% increase year-over-year.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $48.00K, a 96.41% decline year-over-year.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $610.00K, a 60.95% decline year-over-year.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.53M, a 3.16% decline year-over-year.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $4.74M, a 30.70% decline from fiscal 2024.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.85M, a 16.31% decline from fiscal 2023.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $8.18M, a 13.86% decline from fiscal 2022.
- Cue Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $9.50M, a 17.54% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $23.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $23.89M 10-Q · filed 2026-08-14 | $24.50M derived: sum of 3 quarters · filed 2026-08-14 | $26.03M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $48.00K 10-Q · filed 2026-05-14 | $658.00K derived: sum of 2 quarters · filed 2026-05-14 | $2.19M derived: sum of 3 quarters · filed 2026-05-14 | $3.45M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $610.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.14M derived: sum of 2 quarters · filed 2026-03-16 | $3.41M derived: sum of 3 quarters · filed 2026-08-14 | $4.74M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.80M derived: sum of 2 quarters · filed 2026-08-14 | $4.13M 10-Q · filed 2025-11-12 | $5.70M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.60M 10-Q · filed 2026-08-14 | $4.16M derived: sum of 3 quarters · filed 2026-08-14 | $5.75M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $1.34M 10-Q · filed 2026-05-14 | $2.90M derived: sum of 2 quarters · filed 2026-05-14 | $4.48M derived: sum of 3 quarters · filed 2026-05-14 | $6.24M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.15M derived: sum of 2 quarters · filed 2026-03-16 | $4.90M derived: sum of 3 quarters · filed 2026-03-16 | $6.85M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.34M derived: sum of 2 quarters · filed 2025-11-12 | $5.28M 10-Q · filed 2025-11-12 | $7.36M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.70M 10-Q · filed 2025-08-12 | $5.77M derived: sum of 3 quarters · filed 2025-08-12 | $7.85M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.95M 10-Q · filed 2025-05-12 | $4.02M derived: sum of 2 quarters · filed 2025-05-12 | $6.09M derived: sum of 3 quarters · filed 2025-05-12 | $8.13M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.14M derived: sum of 2 quarters · filed 2025-03-31 | $6.18M derived: sum of 3 quarters · filed 2025-03-31 | $8.18M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.11M derived: sum of 2 quarters · filed 2024-11-14 | $6.11M 10-Q · filed 2024-11-14 | $8.22M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.04M 10-Q · filed 2024-08-14 | $6.15M derived: sum of 3 quarters · filed 2024-08-14 | $8.21M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-09 | $4.11M derived: sum of 2 quarters · filed 2024-05-09 | $6.17M derived: sum of 3 quarters · filed 2024-05-09 | $8.48M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.18M derived: sum of 2 quarters · filed 2024-03-28 | $6.49M derived: sum of 3 quarters · filed 2024-03-28 | $9.50M 10-K · filed 2024-03-28 | $9.50M 10-K · filed 2023-03-21 |
| 2022-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.37M derived: sum of 2 quarters · filed 2023-11-03 | $7.38M 10-Q · filed 2023-11-03 | $10.36M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.32M 10-Q · filed 2023-08-08 | $8.29M derived: sum of 3 quarters · filed 2023-08-08 | $11.55M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $3.01M 10-Q · filed 2023-05-09 | $5.99M derived: sum of 2 quarters · filed 2023-05-09 | $9.24M derived: sum of 3 quarters · filed 2023-05-09 | $12.09M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $6.23M derived: sum of 2 quarters · filed 2023-03-21 | $9.08M derived: sum of 3 quarters · filed 2023-03-21 | $11.52M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.11M derived: sum of 2 quarters · filed 2022-11-14 | $8.54M 10-Q · filed 2022-11-14 | $10.82M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.29M 10-Q · filed 2022-08-04 | $7.57M derived: sum of 3 quarters · filed 2022-08-04 | $10.07M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $2.44M 10-Q · filed 2022-05-10 | $4.72M derived: sum of 2 quarters · filed 2022-05-10 | $7.22M derived: sum of 3 quarters · filed 2022-05-10 | $9.74M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $4.78M derived: sum of 2 quarters · filed 2022-03-16 | $7.31M derived: sum of 3 quarters · filed 2022-03-16 | $10.48M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.02M derived: sum of 2 quarters · filed 2021-11-09 | $8.20M 10-Q · filed 2021-11-09 | $10.19M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $5.70M 10-Q · filed 2021-08-09 | $7.69M derived: sum of 3 quarters · filed 2021-08-09 | $9.13M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $3.17M 10-Q · filed 2021-05-10 | $5.17M derived: sum of 2 quarters · filed 2021-05-10 | $6.61M derived: sum of 3 quarters · filed 2021-05-10 | $7.93M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $3.44M derived: sum of 2 quarters · filed 2021-03-09 | $4.75M derived: sum of 3 quarters · filed 2021-03-09 | $6.52M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.76M derived: sum of 2 quarters · filed 2020-11-09 | $4.53M 10-Q · filed 2020-11-09 | $6.54M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $3.08M 10-Q · filed 2020-08-07 | $5.10M derived: sum of 3 quarters · filed 2020-08-07 | $7.83M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $1.77M 10-Q · filed 2020-05-07 | $3.78M derived: sum of 2 quarters · filed 2020-05-07 | $6.51M derived: sum of 3 quarters · filed 2020-05-07 | $7.78M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.74M derived: sum of 2 quarters · filed 2020-03-12 | $6.02M derived: sum of 3 quarters · filed 2020-03-12 | $7.17M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $4.00M derived: sum of 2 quarters · filed 2019-11-07 | $5.16M 10-Q · filed 2019-11-07 | $5.94M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.43M 10-Q · filed 2019-08-08 | $3.21M derived: sum of 3 quarters · filed 2019-08-08 | $3.96M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $1.16M 10-Q · filed 2019-05-08 | $1.93M derived: sum of 2 quarters · filed 2019-05-08 | $2.68M derived: sum of 3 quarters · filed 2019-05-08 | $3.39M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $774.36K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $1.53M derived: sum of 2 quarters · filed 2019-03-14 | $2.23M derived: sum of 3 quarters · filed 2019-03-14 | $2.78M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $751.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $1.46M derived: sum of 2 quarters · filed 2018-11-13 | $2.00M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $1.25M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | $543.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |